85 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
.; and important roles across legal and regulatory affairs at Amgen Inc.
“As a physician, Spyre’s commitment to scientific excellence and patient
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound
8-K
EX-10.1
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment
POS AM
tv2h75urgc
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
u7ew4
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
yb6p1cyg
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
i40aialeymy po3gbs7e
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
EX-3.1
99s7r4kt q5
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
S-8
EX-99.1
abz8elqq
22 Dec 23
Registration of securities for employees
5:00pm